genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2018
Basilea Pharmaceutica
Cancer
Basilea to Develop ArQule’s Cancer Candidate Derazantinib Worldwide Except China Region
Drug Discovery
Basilea Wins Additional $54.8M BARDA Funding to Develop Ceftobiprole for U.S.
Cancer
U.K. Consortium Inks Deal with Basilea to Advance panRAF Inhibitors
Drug Discovery
Astellas Takes Over Isavuconazole Manufacturing and Promotion in U.S., Canada
Drug Discovery
Basilea Wins Up to $89M BARDA Contract to Develop New Antibiotic
News
GSK Pays Basilea £146M Up Front for Approved Dermatology Product Toctino
News
Almirall to Pay Basilea Up To €27 for Approved Eczema Drug in Specific EU Territories and Mexico
Scroll Up
Scroll Up
